Micregen Ltd

Micregen’s purpose is to increase healthspan & prolong the period of quality active life. New treatment and healthcare improvements over the last fifty years have helped save and extend lives. Consequently, we now have an increasing ageing population that suffer with multimorbidity and healthcare systems across the world are under pressure to cope. Solutions to address this issue have the potential to simultaneously deliver substantial economic improvement for global health services whilst providing more benefits to humanity than at any other time in our history. We have a unique understanding of how stem cells can be manipulated to produce optimised stem cell secretions, we call Secretomix® and are exploring the effects of our products on various disease states, with the target of extending the period of living healthily. The Secretomix® platform is designed to create various secretome formulations for different diseases. It is anticipated to produce new therapeutics delivering novel regenerative approaches, which are scalable and are expected to have applications across a wide range of diseases. Stem cell secretomes have been proven to stimulate tissue repair, modulate inflammation and scarring, improve blood flow, and generates a pro-regenerative microenvironment across various organs and tissue types. As a result, Micregen believes that their innovative approach in developing the Secretomix® platform to produce various secretome formulations from it’s first clinical grade master and working cell banks, could change how multiple critical and chronic problems are managed- not just the symptoms, but the root causes of diseases. This approach has been developed from the founders lifetime experience on the use of autologous stem cell secretome therapeutics in cutting-edge biological and regenerative medicine, which has already improved lives and saved world famous sporting careers.